arrow_back Trending Legislation
Share share

Stem Cell Therapies Support: Access to Treatment and Research

This law extends programs supporting stem cell therapies, meaning better access to treatment for patients needing transplants. It secures funding for research and development of new treatment methods, potentially offering hope for future therapies.
Key points
Extension of funding for stem cell transplant programs until 2026, ensuring continuity of treatment.
Increased frequency of advisory council meetings to respond more quickly to patient needs and scientific advancements.
Introduction of regular scientific reviews to evaluate new therapies using adult stem cells and birthing tissues.
Commissioning a report assessing the demand for specialists in regenerative medicine, which may impact the availability of qualified personnel.
article Official text account_balance Process page notifications_active Track this Bill
100%
VOTING RESULTS
2021-04-15
For 415
Against 2
Abstain 0
Full voting results open_in_new
gavel
Status:
Became Law
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
TRANSPLANT Act of 2021
Print number: HR 941
Sponsor: Rep. Matsui, Doris O. [D-CA-6]
Process start date: 2021-02-08
Voting date: 2021-04-15
Meeting no: 1
Voting no: 109
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Stem Cell Therapies Support: Access to Treatment and Research

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 941.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-02-08.

What are the main provisions?

Key points include:

  • Extension of funding for stem cell transplant programs until 2026, ensuring continuity of treatment.
  • Increased frequency of advisory council meetings to respond more quickly to patient needs and scientific advancements.
  • Introduction of regular scientific reviews to evaluate new therapies using adult stem cells and birthing tissues.
  • Commissioning a report assessing the demand for specialists in regenerative medicine, which may impact the availability of qualified personnel.

What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-6].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-15.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 941

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health